Drug Trial Radar · NCT01728064
Safety and Efficacy of EPI-743 in Patients With Friedreich's Ataxia
Last checked: Nov 20, 2026Latest source record: Aug 31, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
60
Planned (sponsor's estimate)
Start
Dec 31, 2012
Primary completion
Oct 31, 2015
Study completion Feb 29, 2016
Sponsor
- Lead sponsor
- PTC TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Nov 16, 2012
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 45 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to examine the effects of EPI-743 on visual function and neurologic function in patients with Friedreich's ataxia.
Conditions
- Friedreich's Ataxia
Interventions
PlaceboDrug
Placebo capsules
EPI-743 400 mgDrug
EPI-743 200 mgDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Visual Function
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
University of California Los Angeles
Los Angeles, California
University of South Florida
Tampa, Florida
Childrens Hospital of Philadelphia
Philadelphia, Pennsylvania
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.